Evidence map›Paper›PMID 36324804›Full record

ArticlebioRxiv : the preprint server for biology2022

Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response.

Anamika Patel, Sanjeev Kumar, Lilin Lai, Chennareddy Chakravarthy, Rajesh Valanparambil, Elluri Seetharami Reddy, Kamalvishnu Gottimukkala, Prashant Bajpai, Dinesh Ravindra Raju, Venkata Viswanadh Edara and 18 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 4 institutions in 2 countries.

Anamika PatelDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.
Sanjeev KumarICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Lilin LaiDepartment of Pediatrics, Emory National Primate Center, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Chennareddy ChakravarthyDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Rajesh ValanparambilDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Elluri Seetharami ReddyICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Kamalvishnu GottimukkalaICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Prashant BajpaiICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Dinesh Ravindra RajuDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.
Venkata Viswanadh EdaraDepartment of Pediatrics, Emory National Primate Center, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Meredith E Davis-GardnerDepartment of Pediatrics, Emory National Primate Center, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Susanne LindermanDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Kritika DixitICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Pragati SharmaICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Grace MantusDepartment of Pediatrics, Emory National Primate Center, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Narayanaiah CheedarlaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Hans P VerkerkeDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Filipp FrankDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.
Andrew S NeishDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
John D RobackDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Carl W DavisDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Jens WrammertDepartment of Pediatrics, Emory National Primate Center, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Rafi AhmedDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Mehul S SutharDepartment of Pediatrics, Emory National Primate Center, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Amit SharmaStructural Parasitology Group, International Center for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Kaja Murali-KrishnaICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Anmol ChandeleICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi, 110067, India.
Eric A OrtlundDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.
Emory University · USInternational Centre for Genetic Engineering and Biotechnology · INBrigham and Women's Hospital · USGeorgia Institute of Technology · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
Medical Scientist Training ProgramT32GM142617 · NIGMS · EMORY UNIVERSITY · PI Jason Yustein · 2022 to 2026
$7.0M
NIGMS NIH HHS T32 GM008169NIGMS NIH HHS T32 GM142617
6 · The paper itself

Abstract

A detailed understanding of the molecular features of the neutralizing epitopes developed by viral escape mutants is important for predicting and developing vaccines or therapeutic antibodies against continuously emerging SARS-CoV-2 variants. Here, we report three human monoclonal antibodies (mAbs) generated from COVID-19 recovered individuals during first wave of pandemic in India. These mAbs had publicly shared near germline gene usage and potently neutralized Alpha and Delta, but poorly neutralized Beta and completely failed to neutralize Omicron BA.1 SARS-CoV-2 variants. Structural analysis of these three mAbs in complex with trimeric spike protein showed that all three mAbs are involved in bivalent spike binding with two mAbs targeting class-1 and one targeting class-4 Receptor Binding Domain (RBD) epitope. Comparison of immunogenetic makeup, structure, and function of these three mAbs with our recently reported class-3 RBD binding mAb that potently neutralized all SARS-CoV-2 variants revealed precise antibody footprint, specific molecular interactions associated with the most potent multi-variant binding / neutralization efficacy. This knowledge has timely significance for understanding how a combination of certain mutations affect the binding or neutralization of an antibody and thus have implications for predicting structural features of emerging SARS-CoV-2 escape variants and to develop vaccines or therapeutic antibodies against these.

Identifiers

PMID36324804
PMCPMC9628201
OpenAlexW4307283353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.